Kamada Ltd. (KMDA) 株式分析

企業概要

Kamada Ltd. operates as a specialized manufacturer and distributor of plasma-derived protein therapeutics, focusing on the production of critical medical products such as KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for preventing cytomegalovirus disease in various organ transplant recipients, and VARIZIG for post-exposure rabies prophylaxis. The company functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on niche pharmaceutical solutions rather than mass-market drugs. As of the latest available data, Kamada Ltd. holds a market capitalization of $492.01M and generated annual revenue of $180.46M while employing a workforce of 462 individuals. These financial metrics indicate that the company occupies a mid-cap position in the specialty pharmaceutical landscape, possessing sufficient scale to fund operations but remaining distinct from the largest biotechnology conglomerates. The combination of specialized product indications and a dedicated employee base suggests a business model reliant on high-margin, low-volume therapeutic interventions essential for public health and transplant medicine.

財務健全性

The company reported a trailing twelve-month revenue of $180.46M with a corresponding net income of $20.20M and an EBITDA of $39.51M. The significant gap between the $180.46M in revenue and the $20.20M in net income reveals a cost structure where approximately 88.8% of revenue is consumed by operating expenses, including the costs of goods sold and administrative overhead required to produce specialized biologics. Free cash flow stands at $7.59M, which represents the actual cash remaining after capital expenditures and operating expenses, providing the company with financial flexibility to manage liquidity needs without relying heavily on external financing. The gross margin is recorded at 42.3%, indicating that the company retains a substantial portion of revenue after direct production costs, typical for plasma-derived products. The operating margin is 7.9%, reflecting the efficiency of the company's core business operations after covering all selling, general, and administrative expenses. The profit margin is 11.2%, which shows the final percentage of revenue that translates into actual profit for shareholders. Regarding liquidity and leverage, the company holds cash of $75.47M against total debt of $11.56M, resulting in a conservative balance sheet profile with a debt-to-equity ratio of 4.30. The current ratio is 4.07, a figure that indicates strong short-term liquidity as the company possesses more than four times the current assets necessary to cover its current liabilities. Return on equity is 7.6% and return on assets is 4.4%, metrics that reveal the effectiveness of management in generating profits relative to the equity invested and the total assets employed, respectively.

バリュエーション評価

Kamada Ltd. trades with a trailing P/E ratio of 24.31 and a forward P/E of 14.34, where the substantial difference between these two metrics implies that the market expects earnings to decline significantly in the coming year. The price-to-book ratio is 1.82, indicating that the market values the company at a premium of 82% over its net asset book value, which often reflects the value of intangible assets like intellectual property and brand equity in the pharmaceutical sector. Alternative valuation metrics such as the price-to-sales ratio of 2.73 and the EV/EBITDA of 10.81 provide additional context, suggesting the stock is priced relative to its sales volume and enterprise value relative to earnings before interest, taxes, depreciation, and amortization. The 52-week high is $9.35 and the 52-week low is $5.54, placing the current trading price within a specific volatility range defined by these historical extremes. The beta value is 0.31, a figure that indicates the stock's price volatility is significantly lower than the broader market, suggesting it behaves as a defensive position with low correlation to general market movements.

Growth & Income

Revenue growth for the year-over-year period is 14.5%, while earnings growth is -14.1%, indicating that earnings are growing slower than revenue and, in this specific period, have contracted despite top-line expansion. This divergence suggests that the company is experiencing a deceleration in profitability despite increasing sales, which may be attributed to rising input costs or one-time expenses affecting the bottom line. Regarding income distribution, the company currently has a dividend yield of 2.9% but maintains a payout ratio of 0.0%, meaning no dividends are paid to shareholders. This lack of a payout ratio implies that the company reinvests its earnings into growth initiatives, research, or balance sheet strengthening rather than distributing cash to investors. The overall growth and income profile presents a scenario of revenue expansion coupled with a temporary earnings contraction, supported by a strong balance sheet but without current cash distributions to equity holders.